Diav-Citrin O, Shechtman S, Arnon J, Ornoy A
Israeli Teratogen Information Service, Laboratory of Teratology, Jerusalem, Israel.
Neurology. 2001 Jul 24;57(2):321-4. doi: 10.1212/wnl.57.2.321.
The Israeli Teratogen Information Service prospectively followed up 210 pregnancies with first trimester carbamazepine exposure. Pregnancy outcome was compared with that of two overlapping controls, matched and general (n = 629), exposed to nonteratogenic agents. Our study suggests a twofold increase in the rate of major congenital anomalies (12/160 [carbamazepine] versus 18/560 [general control]; relative risk 2.24; 95% CI 1.1-4.56) and a birth weight reduction of approximately 250 g after in utero exposure to carbamazepine.
